Yunnan Baiyao Group Co., Ltd. operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Yunnan Baiyao Group Co., Ltd. with three other
companies in this sector in China:
Realcan Pharmaceutical Co Ltd
sales of 23.29 billion Chinese Renmimbi [US$3.35 billion]
of which 100%
was Medical Devices Sales),
Huadong Medicine Company Limited
(27.83 billion Chinese Renmimbi [US$4.00 billion]
of which 78%
was Commerce), and
C.Q. Pharmaceutical Holding Co Ltd
(23.04 billion Chinese Renmimbi [US$3.32 billion]
of which 92%
was Drug Sales).
During the year ended December of 2017, sales at
Yunnan Baiyao Group Co., Ltd. were 24.31 billion Chinese Renmimbi (US$3.50 billion).
increase of 8.5%
versus 2016, when the company's sales were 22.41 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Yunnan Baiyao Group Co., Ltd.
(and since 2012, sales have increased a total of 78%).
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
35.4% in 2017, from
48.48 million Chinese Renmimbi to 65.63 million Chinese Renmimbi.
Not all segments of Yunnan Baiyao Group Co., Ltd. experienced an increase in sales in 2017:
sales of Planting Industry fell 53.2% to 2.07 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Yunnan Baiyao Group Co., Ltd. also experienced decreases in sales in
Technology Development (down 9.4% to 1.34 million Chinese Renmimbi)